Axios CEO Joseph Saba will join healthcare business leaders from around the world next week in Shanghai, China, to discuss the “Challenges and Opportunities of Global Market Access for Pharmaceuticals," including emerging and developed markets.
| Location: To join the discussion, email axios@axiosint.com to request your invitation and join via Weblink. |
What will be discussed?
Organized by the China Europe International Business School (CEIBS), Dr. Saba will share his insights from 30+ years of experience designing and implementing access programs in low- and middle-income countries during a panel on access challenges in emerging markets. Panelists will explore innovative access to treatment models – including patient assistance programs and differential pricing – as well as China’s access experience, learnings and opportunities to date.
Panelists include:
- Paola Barbarino, CEO, Alzheimer Disease International, London, UK
- Prof. Ding Jinxi, Executive Deputy Dean of Graduate School of Chinese Pharmaceutical University, Nanjing, China
- Jon Fairest, Head of Global Health Unit, Sanofi, Paris, France
- Dr. Joseph Saba, CEO, Axios International, Paris, France
- Dr. Wu Xiaobin, President and COO, BeiGene, Shanghai, China
- Moderator: Eric Bouteiller, Adjunct Professor, China Europe International Business School, Shanghai, China
In addition, a separate panel will be held to discuss how to access the latest innovations in developed markets, including access challenges in precision medicine, diagnostic and digital tools to improve outcomes and the role of patient organizations
Panelists include:
- Christoph Glaetzer, Chief Global Value and Access Officer, Johnson & Johnson Innovative Medicine, New Brunswick, NJ, USA
- Francois Houÿez, Information & Access to Therapies Director & Health Policy Advisor, EURORDIS, Brussels Belgium
- Professor Hiroshi Nakamura, Dean, Keio Business School, Tokyo, Japan
- Moderator: Annie Chicoye, Senior Lecturer, Sciences Po Paris, France
Why this matters:
Pharmaceutical innovation is accelerating, but effective access to these innovations is not following the same pace. While issues in emerging markets and more developed countries may differ, both face significant treatment challenges. Shanghai, the world’s second-largest pharmaceutical market, is an ideal place to discuss these issues, thanks to China’s rapid progress in pharmaceutical innovation and economic development.
CEIBS is a business school co-founded in 1994 by the Chinese government and European Union, with campuses in China, Europe and Africa; its Global EMBA program was recently ranked #1 in the Financial Times’ 2024 EMBA rankings.
